<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13318">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01955707</url>
  </required_header>
  <id_info>
    <org_study_id>101SK201</org_study_id>
    <secondary_id>EUDRA CT NO: 2013‐001514‐15</secondary_id>
    <nct_id>NCT01955707</nct_id>
  </id_info>
  <brief_title>Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke</brief_title>
  <acronym>ACTION</acronym>
  <official_title>A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen Idec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen Idec</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine whether one 300 mg dose of intravenous
      (IV) BG00002 reduces change in infarct volume from Baseline to Day 5 on magnetic resonance
      imaging (MRI) in subjects with acute ischemic stroke when given at ≤6 hours or at &gt;6 to ≤9
      hours from when they were last known normal (LKN).

      The secondary objectives of this study in this study population are as follows:  To assess
      the efficacy of BG00002 on change in infarct volume from Baseline to Day 30; To assess
      efficacy of BG00002 on change in infarct volume from 24 hours to Day 5 and Day 30;  To
      assess the efficacy of BG00002 on clinical measures of stroke outcome;  To assess the safety
      of BG00002 in subjects with acute ischemic stroke
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Infarct Volume from Baseline (Diffusion-Weighted Imaging [DWI]) to Day 5 (Fluid-Attenuated Inversion Recovery [FLAIR])</measure>
    <time_frame>Day 5</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Infarct Volume From Baseline (DWI) to Day 30 (FLAIR)</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Infarct Volume From 24 hours (DWI) to Day 5 and Day 30 (FLAIR)</measure>
    <time_frame>Up to Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in National Institute of Health Stroke Scale (NIHSS) Score from Baseline to 24 hours, Day 5, Day 30, and Day 90</measure>
    <time_frame>Up to Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS) distribution at Day 5, Day 30, and Day 90</measure>
    <time_frame>Up to Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index at Day 5, Day 30, and Day 90</measure>
    <time_frame>Up to Day 90</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who experience Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 90</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>BG00002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single dose of BG00002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a single dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BG00002</intervention_name>
    <description>300 mg single intravenous injection</description>
    <arm_group_label>BG00002</arm_group_label>
    <other_name>Natalizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single intravenous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of acute ischemic stroke.

          -  Score of ≥6 points on the National Institute of Health Stroke Scale (NIHSS) at
             Screening.

          -  At least 1 acute infarct with largest diameter of more than 2 cm on Baseline brain
             diffusion-weighted imaging (DWI).

          -  Participants who have received reperfusion therapy may be eligible to participate but
             must meet all eligibility criteria and perform the Baseline study magnetic resonance
             imaging (MRI) after reperfusion therapy has been completed.

          -  Subjects of childbearing potential must practice effective contraception during the
             study and be willing and able to continue contraception for at least 3 months after
             their dose of study treatment.

        Key Exclusion Criteria:

          -  Presence of any intracranial hemorrhage (ICH) on head computed tomography (CT) or
             non-petechial ICH on screening MRI.

          -  Stroke isolated to the brainstem.

          -  Presence of coma

          -  Expected to die OR unable to be evaluated within 5 days.

          -  Hypotension requiring the use of intravenous (IV) vasopressor support or systolic
             blood pressure &lt;90 mmHg at the time of randomization.

          -  Known prior treatment with natalizumab.

          -  Immunocompromised subjects, as determined by the Investigator.

          -  History of progressive multifocal leukoencephalopathy (PML).

          -  Contraindications to MRI, e.g., implanted pacemaker or other contraindicated
             implanted metal devices, history of or risk for side effects from gadolinium, or
             claustrophobia that cannot be medically managed.

        NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen Idec</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Biogen Idec Investigator</last_name>
    <email>clinicaltrials@biogenidec.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minneapolis Clinic of Neurology Ltd</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center PRIME</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Stroke Center</name>
      <address>
        <city>Portlnad</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Altenburger Land</name>
      <address>
        <city>Altenburg</city>
        <zip>4600</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurologishce Klinik Bad Neustadt/Saale</name>
      <address>
        <city>Bad Neustadt</city>
        <zip>97616</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Idar-Oberstein GmbH</name>
      <address>
        <city>Idar-Oberstein</city>
        <zip>55743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 7, 2014</lastchanged_date>
  <firstreceived_date>September 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
